Bright Minds Biosciences Announces Resignation of Board Member
09 janv. 2023 16h05 HE
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
02 déc. 2022 19h07 HE
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Announces Non-Brokered Private Placement
28 nov. 2022 06h50 HE
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
23 nov. 2022 11h35 HE
|
Bright Minds Biosciences
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE)...
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
07 sept. 2022 06h50 HE
|
Bright Minds Biosciences
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
31 août 2022 06h50 HE
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
30 août 2022 15h35 HE
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Comments on Recent Trading Activity
18 août 2022 15h34 HE
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
27 juin 2022 06h50 HE
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
12 mai 2022 06h50 HE
|
Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds...